TY - JOUR
T1 - Neurodevelopmental disabilities in children with intermediate and premutation range fragile X cytosine-guanine-guanine expansions
AU - Renda, Meredith M.
AU - Voigt, Robert G.
AU - Babovic-Vuksanovic, Dusica
AU - Highsmith, W. Edward
AU - Vinson, Sherry S.
AU - Sadowski, Christine M.
AU - Hagerman, Randi J.
N1 - Funding Information:
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Randi J. Hagerman, MD, has received funding from Roche, Novartis, Seaside Therapeutics, Curemark, and Forest for treatment studies in fragile X syndrome or autism.
PY - 2014/3
Y1 - 2014/3
N2 - To determine the range of neurodevelopmental diagnoses associated with intermediate (45-54 repeats) and premutation (55-200 repeats) range cytosine-guanine-guanine fragile X expansions, the medical records of children with intermediate or premutation range expansions were retrospectively reviewed, and all neurodevelopmental diagnoses were abstracted. Twenty-nine children (9 female, 20 male; age, 13 months to 17 years) with intermediate (n = 25) or premutation (n = 4) range expansions were identified with neurodevelopmental diagnoses, including global developmental delay/intellectual disability (n = 15), language and learning disorders (n = 9), attention-deficit hyperactivity disorder (n = 5), epilepsy (n = 5), and motor disorders (n = 12), including 2 boys younger than 4 years of age with tremor and ataxia. Thus, children with intermediate or premutation range fragile X cytosine-guanine-guanine expansions may be more susceptible than children without such expansions to other processes, both genetic and environmental, that contribute to neurodevelopmental disability.
AB - To determine the range of neurodevelopmental diagnoses associated with intermediate (45-54 repeats) and premutation (55-200 repeats) range cytosine-guanine-guanine fragile X expansions, the medical records of children with intermediate or premutation range expansions were retrospectively reviewed, and all neurodevelopmental diagnoses were abstracted. Twenty-nine children (9 female, 20 male; age, 13 months to 17 years) with intermediate (n = 25) or premutation (n = 4) range expansions were identified with neurodevelopmental diagnoses, including global developmental delay/intellectual disability (n = 15), language and learning disorders (n = 9), attention-deficit hyperactivity disorder (n = 5), epilepsy (n = 5), and motor disorders (n = 12), including 2 boys younger than 4 years of age with tremor and ataxia. Thus, children with intermediate or premutation range fragile X cytosine-guanine-guanine expansions may be more susceptible than children without such expansions to other processes, both genetic and environmental, that contribute to neurodevelopmental disability.
KW - developmental disability
KW - fragile X syndrome
KW - premutation
UR - http://www.scopus.com/inward/record.url?scp=84894428985&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84894428985&partnerID=8YFLogxK
U2 - 10.1177/0883073812469723
DO - 10.1177/0883073812469723
M3 - Article
C2 - 23266944
AN - SCOPUS:84894428985
SN - 0883-0738
VL - 29
SP - 326
EP - 330
JO - Journal of Child Neurology
JF - Journal of Child Neurology
IS - 3
ER -